Tocagen Continues Merger-Fueled Upswing
Tocagen (TOCA) stock shot up as the company follows through its previous announcement about a merger with Forte Biosciences, an obscure pharmaceuticals firm with FB-401 as its lead candidate. FB-401 is a topical drug designed to treat inflammatory skin conditions. The drug is claimed to have shown promise during its Phase 1/2 study. The results from the study are expected to be published during mid 2020. It is also expected that a Phase 2 trial for evaluating the impact of this drug candidate on treating atopic dermatitis will be